Report Detail
Global (United States, European Union and China) Myelodysplastic Syndrome (MDS) Treatment Market Research Report 2019-2025
- RnM3579327 |
- 22 July, 2019 |
- Global |
- 110 Pages |
- QYResearch |
- Pharma & Healthcare
Myelodysplastic (MDS) syndrome is a type of bone marrow disorder, where bone marrow is unable to produce healthy and mature blood cells. The immature blood cells called as blasts, get stored in the bone marrow and blood and obstruct the natural function of the hematological system which results in depletion of healthy red blood cells, platelets, and white blood cells. Myelodysplastic syndrome is usually seen in geriatric population and more often in older men than women. This syndrome is characterized by certain chromosomal mutations in Janus Kinase gene which include deletion of q arm in one or more chromosomes and complete deletion of chromosome 5 or 7 and an extra copy of chromosome 8.
According to the American Cancer Society, the incidence rate for myelodysplastic syndrome is 13,000 new cases each year which happens at a rate of 4.8 cases per 100,000 people. This trend is heavily affected or rather influenced by the average age of the population which, according to the World Health Organization (WHO), is increasing and is expected to double from 12% to 22% between 2015 and 2050.
In 2019, the market size of Myelodysplastic Syndrome (MDS) Treatment is 2210 million US$ and it will reach 5760 million US$ in 2025, growing at a CAGR of 12.7% from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Myelodysplastic Syndrome (MDS) Treatment.
This report studies the global market size of Myelodysplastic Syndrome (MDS) Treatment, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
This study presents the Myelodysplastic Syndrome (MDS) Treatment sales volume, revenue, market share and growth rate for each key company, and also covers the breakdown data (sales, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.
In global market, the following companies are covered:
Novartis AG
Celgene Corporation
Otsuka Pharmaceutical Co., Ltd
Sandoz Inc
Dr Reddys Laboratories Limited
Pharmascience Inc
Accord Healthcare Ltd
Mylan N.V.
Market Segment by Product Type
Azacitidine
Lenalidomide
Decitabine
Deferasirox
Market Segment by Application
Refractory cytopenia with unilineage dysplasia
Refractory anemia with ringed sideroblasts
Others
Key Regions split in this report: breakdown data for each region.
United States
China
European Union
Rest of World (Japan, Korea, India and Southeast Asia)
The study objectives are:
To analyze and research the Myelodysplastic Syndrome (MDS) Treatment status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
To present the key Myelodysplastic Syndrome (MDS) Treatment manufacturers, presenting the sales, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market
In this study, the years considered to estimate the market size of Myelodysplastic Syndrome (MDS) Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
Table of Contents
1 Report Overview
- 1.1 Study Scope
- 1.2 Major Manufacturers Covered in This Report
- 1.3 Market Segment by Type
- 1.3.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size Growth Rate by Type (2019-2025)
- 1.3.2 Azacitidine
- 1.3.3 Lenalidomide
- 1.3.4 Decitabine
- 1.3.5 Deferasirox
- 1.4 Market Segment by Application
- 1.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Share by Application (2019-2025)
- 1.4.2 Refractory cytopenia with unilineage dysplasia
- 1.4.3 Refractory anemia with ringed sideroblasts
- 1.4.4 Others
- 1.5 Study Objectives
- 1.6 Years Considered
2 Global Growth Trends
- 2.1 Global Myelodysplastic Syndrome (MDS) Treatment Market Size
- 2.1.1 Global Myelodysplastic Syndrome (MDS) Treatment Revenue 2014-2025
- 2.1.2 Global Myelodysplastic Syndrome (MDS) Treatment Sales 2014-2025
- 2.2 Myelodysplastic Syndrome (MDS) Treatment Growth Rate by Regions
- 2.2.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Regions 2014-2019
- 2.2.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue by Regions 2014-2019
- 2.3 Industry Trends
- 2.3.1 Market Top Trends
- 2.3.2 Market Drivers
3 Market Share by Manufacturers
- 3.1 Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers
- 3.1.1 Myelodysplastic Syndrome (MDS) Treatment Sales by Manufacturers 2014-2019
- 3.1.2 Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Manufacturers 2014-2019
- 3.2 Revenue by Manufacturers
- 3.2.1 Myelodysplastic Syndrome (MDS) Treatment Revenue by Manufacturers (2014-2019)
- 3.2.2 Myelodysplastic Syndrome (MDS) Treatment Revenue Share by Manufacturers (2014-2019)
- 3.2.3 Global Myelodysplastic Syndrome (MDS) Treatment Market Concentration Ratio (CR5 and HHI)
- 3.3 Myelodysplastic Syndrome (MDS) Treatment Price by Manufacturers
- 3.4 Key Manufacturers Myelodysplastic Syndrome (MDS) Treatment Plants/Factories Distribution and Area Served
- 3.5 Date of Key Manufacturers Enter into Myelodysplastic Syndrome (MDS) Treatment Market
- 3.6 Key Manufacturers Myelodysplastic Syndrome (MDS) Treatment Product Offered
- 3.7 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type
- 4.1 Sales and Revenue for Each Type
- 4.1.1 Azacitidine Sales and Revenue (2014-2019)
- 4.1.2 Lenalidomide Sales and Revenue (2014-2019)
- 4.1.3 Decitabine Sales and Revenue (2014-2019)
- 4.1.4 Deferasirox Sales and Revenue (2014-2019)
- 4.2 Global Myelodysplastic Syndrome (MDS) Treatment Sales Market Share by Type
- 4.3 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Market Share by Type
- 4.4 Myelodysplastic Syndrome (MDS) Treatment Price by Type
5 Market Size by Application
- 5.1 Overview
- 5.2 Global Myelodysplastic Syndrome (MDS) Treatment Sales by Application
6 United States
- 6.1 United States Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Company
- 6.2 United States Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Type
- 6.3 United States Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Application
7 European Union
- 7.1 European Union Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Company
- 7.2 European Union Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Type
- 7.3 European Union Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Application
8 China
- 8.1 China Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Company
- 8.2 China Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Type
- 8.3 China Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Application
9 Rest of World
- 9.1 Rest of World Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Company
- 9.2 Rest of World Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Type
- 9.3 Rest of World Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Application
- 9.4 Rest of World Myelodysplastic Syndrome (MDS) Treatment Breakdown Data by Countries
- 9.4.1 Rest of World Myelodysplastic Syndrome (MDS) Treatment Sales by Countries
- 9.4.2 Rest of World Myelodysplastic Syndrome (MDS) Treatment Revenue by Countries
- 9.4.3 Japan
- 9.4.4 Korea
- 9.4.5 India
- 9.4.6 Southeast Asia
10 Company Profiles
- 10.1 Novartis AG
- 10.1.1 Novartis AG Company Details
- 10.1.2 Company Description and Business Overview
- 10.1.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome (MDS) Treatment
- 10.1.4 Myelodysplastic Syndrome (MDS) Treatment Product Introduction
- 10.1.5 Novartis AG Recent Development
- 10.2 Celgene Corporation
- 10.2.1 Celgene Corporation Company Details
- 10.2.2 Company Description and Business Overview
- 10.2.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome (MDS) Treatment
- 10.2.4 Myelodysplastic Syndrome (MDS) Treatment Product Introduction
- 10.2.5 Celgene Corporation Recent Development
- 10.3 Otsuka Pharmaceutical Co., Ltd
- 10.3.1 Otsuka Pharmaceutical Co., Ltd Company Details
- 10.3.2 Company Description and Business Overview
- 10.3.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome (MDS) Treatment
- 10.3.4 Myelodysplastic Syndrome (MDS) Treatment Product Introduction
- 10.3.5 Otsuka Pharmaceutical Co., Ltd Recent Development
- 10.4 Sandoz Inc
- 10.4.1 Sandoz Inc Company Details
- 10.4.2 Company Description and Business Overview
- 10.4.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome (MDS) Treatment
- 10.4.4 Myelodysplastic Syndrome (MDS) Treatment Product Introduction
- 10.4.5 Sandoz Inc Recent Development
- 10.5 Dr Reddys Laboratories Limited
- 10.5.1 Dr Reddys Laboratories Limited Company Details
- 10.5.2 Company Description and Business Overview
- 10.5.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome (MDS) Treatment
- 10.5.4 Myelodysplastic Syndrome (MDS) Treatment Product Introduction
- 10.5.5 Dr Reddys Laboratories Limited Recent Development
- 10.6 Pharmascience Inc
- 10.6.1 Pharmascience Inc Company Details
- 10.6.2 Company Description and Business Overview
- 10.6.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome (MDS) Treatment
- 10.6.4 Myelodysplastic Syndrome (MDS) Treatment Product Introduction
- 10.6.5 Pharmascience Inc Recent Development
- 10.7 Accord Healthcare Ltd
- 10.7.1 Accord Healthcare Ltd Company Details
- 10.7.2 Company Description and Business Overview
- 10.7.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome (MDS) Treatment
- 10.7.4 Myelodysplastic Syndrome (MDS) Treatment Product Introduction
- 10.7.5 Accord Healthcare Ltd Recent Development
- 10.8 Mylan N.V.
- 10.8.1 Mylan N.V. Company Details
- 10.8.2 Company Description and Business Overview
- 10.8.3 Sales, Revenue and Market Share of Myelodysplastic Syndrome (MDS) Treatment
- 10.8.4 Myelodysplastic Syndrome (MDS) Treatment Product Introduction
- 10.8.5 Mylan N.V. Recent Development
11 Value Chain and Sales Channels Analysis
- 11.1 Value Chain Analysis
- 11.2 Sales Channels Analysis
- 11.2.1 Myelodysplastic Syndrome (MDS) Treatment Sales Channels
- 11.2.2 Myelodysplastic Syndrome (MDS) Treatment Distributors
- 11.3 Myelodysplastic Syndrome (MDS) Treatment Customers
12 Market Forecast
- 12.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales and Revenue Forecast 2019-2025
- 12.2 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Type
- 12.3 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Application
- 12.4 Myelodysplastic Syndrome (MDS) Treatment Forecast by Regions
- 12.4.1 Global Myelodysplastic Syndrome (MDS) Treatment Sales Forecast by Regions 2019-2025
- 12.4.2 Global Myelodysplastic Syndrome (MDS) Treatment Revenue Forecast by Regions 2019-2025
- 12.5 United States Market Forecast
- 12.6 European Union Market Forecast
- 12.7 China Market Forecast
- 12.8 Rest of World
- 12.8.1 Japan
- 12.8.2 Korea
- 12.8.3 India
13 Research Findings and Conclusion
14 Appendix
- 14.1 Research Methodology
- 14.1.1 Methodology/Research Approach
- 14.1.1.1 Research Programs/Design
- 14.1.1.2 Market Size Estimation
- 14.1.1.3 Market Breakdown and Data Triangulation
- 14.1.2 Data Source
- 14.1.2.1 Secondary Sources
- 14.1.2.2 Primary Sources
- 14.1.1 Methodology/Research Approach
- 14.2 Author Details
Summary:
Get latest Market Research Reports on Myelodysplastic Syndrome (MDS) Treatment. Industry analysis & Market Report on Myelodysplastic Syndrome (MDS) Treatment is a syndicated market report, published as Global (United States, European Union and China) Myelodysplastic Syndrome (MDS) Treatment Market Research Report 2019-2025. It is complete Research Study and Industry Analysis of Myelodysplastic Syndrome (MDS) Treatment market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
